Universal Ibogaine Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBOGF research report →
About the company
Universal Ibogaine Inc. , a life sciences enterprise, focuses on developing, acquiring, and operating addiction treatment centers across Canada. The company is additionally preparing to launch clinical trials aimed at researching ibogaine's potential therapeutic applications for addiction.
- CEO
- Nicholas Peter Karos
- IPO
- 2022
- Employees
- 7
- HQ
- Calgary, AB, CA
Price Chart
- Market Cap
- $8.32M
- P/E
- -4.17
- P/S
- 1.46
- P/B
- 5.67
- EV/EBITDA
- -31.85
- Div Yield
- 0.00%
- Gross Margin
- 9.01%
- Op Margin
- 24.83%
- Net Margin
- -34.56%
- ROE
- -120.71%
- ROIC
- 9.36%
- Revenue
- $1.07M · 0.00%
- Net Income
- $-10,496,202 · -171.41%
- EPS
- $-0.06 · -82.85%
- Op Income
- $497.15K
- FCF YoY
- -36.28%
- 52W High
- $0.35
- 52W Low
- $0.00
- 50D MA
- $0.03
- 200D MA
- $0.01
- Beta
- 4.37
- Avg Volume
- 1.42M
Get TickerSpark's AI analysis on IBOGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IBOGF coverage
Recent articles, reports, and earnings notes.
No research on IBOGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IBOGF report →Similar companies
Peers in the same neighborhood.